27 Jun 12:59
by Catherine Offord
Claim that a blood sample’s mix of microbes can reveal a tumor spawned other research and a company to commercialize the findings
26 Jun 18:00
by Jamie D. Liu,
Kelly E. VanTreeck,
William A. Marston,
Virginie Papadopoulou,
Sarah E. Rowe
Bacterial biofilms pose a significant clinical challenge because they are highly resistant to host immune responses and antibiotic treatments. This review delves into the reasons behind the difficulty in treating biofilms and investigates the potential of ultrasound-mediated drug delivery as a method to address various in vivo biofilm infections.
Abstract
Bacterial biofilms are a significant concern in various medical contexts due to their resilience to our immune system as well as antibiotic therapy. Biofilms often require surgical removal and frequently lead to recurrent or chronic infections. Therefore, there is an urgent need for improved strategies to treat biofilm infections. Ultrasound-mediated drug delivery is a technique that combines ultrasound application, often with the administration of acoustically-active agents, to enhance drug delivery to specific target tissues or cells within the body. This method involves using ultrasound waves to assist in the transportation or activation of medications, improving their penetration, distribution, and efficacy at the desired site. The advantages of ultrasound-mediated drug delivery include targeted and localized delivery, reduced systemic side effects, and improved efficacy of the drug at lower doses. This review scrutinizes recent advances in the application of ultrasound-mediated drug delivery for treating biofilm infections, focusing on in vivo studies. We examine the strengths and limitations of this technology in the context of wound infections, device-associated infections, lung infections and abscesses, and discuss current gaps in knowledge and clinical translation considerations.
21 Jun 15:06
by Zhen ChangDan GaoLiying LiaoJunqing SunGen ZhangXue ZhangFeiran WangChunrui LiBabayemi Olawale OladejoShihua LiYan ChaiYongfei HuXuancheng LuHaixia XiaoJianxun QiZhihai ChenFeng GaoYan WuaDepartment of Pathogen Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, ChinabChinese Academy of Sciences Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, ChinacCollege of Veterinary Medicine, Shanxi Agricultural University, Jinzhong, Shanxi 030801, ChinadFaculty of Health Sciences, University of Macau, Macau SAR 999078, ChinaeDepartment of Microbiology, Federal University of Technology, PMB704, Akure, NigeriafCollege of Veterinary Medicine, China Agricultural University, Beijing 100193, ChinagNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinahLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, ChinaiCenter of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Proceedings of the National Academy of Sciences, Volume 121, Issue 24, June 2024.
21 Jun 15:03
by Theo SagmeisterNina GubensäkChristoph BuhlhellerChristoph GriningerMarkus EderAnđela ÐordićClaudia MillánAna MedinaPedro Alejandro Sánchez MurciaFrancesca BerniUlla HynönenDjenana VejzovićElisabeth DamischNatalia KulminskayaLukas PetrowitschMonika ObererAiri PalvaNermina MalanovićJeroen CodéeWalter KellerIsabel UsónTea Pavkov-KelleraInstitute of Molecular Biosciences, University of Graz, Graz, Austria 8010bStructural Biology Unit, Institute of Molecular Biology of Barcelona, Spanish National Research Council, Barcelona 08028, SpaincLaboratory of Computer-Aided Molecular Design, Division of Medicinal Chemistry, Otto-Loewi Research Center, Medical University of Graz, Graz, Austria 8010dDepartment of Bio-Organic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden 2333, The NetherlandseDepartment of Basic Veterinary Sciences, Division of Microbiology and Epidemiology, University of Helsinki, Helsinki 00100, FinlandfField of Excellence BioHealth, University of Graz, Graz 8010, AustriagBioTechMed-Graz, University of Graz, Graz 8010, AustriahInstitució Catalana de Recerca i Estudis Avançats, Barcelona 08003, Spain
Proceedings of the National Academy of Sciences, Volume 121, Issue 24, June 2024.
20 Jun 21:20
An innovative project to re-purpose existing drugs for their potential as antibiotics has uncovered a highly promising candidate with a potent and unique way of killing drug resistant bacteria.
19 Jun 13:24
by Andre Augusto Botêga Silva
Shock. 2024 Jun 18. doi: 10.1097/SHK.0000000000002399. Online ahead of print.
ABSTRACT
Mitochondrial dysfunction is a recognized feature of sepsis, characterized by ultrastructural damage, diminished oxidative phosphorylation, and depletion of mitochondrial antioxidant capacity observed in deceased septic patients. Lipopolysaccharide (LPS) tolerance induces a controlled response to sepsis. This study aimed to evaluate the function of tolerant mitochondria after cecal ligation and puncture (CLP)-induced sepsis. Mytochondrial oxygen consumption was determined using polarography. Extraction and quantification of RNA for the expression of Tfam, Nrf-1 and Ppargc-1α; and Respiratory complex activity were measured. CLP-tolerant animals presented preserved respiratory rates of S3 and S4 and a ratio of respiratory control (RCR) compared to CLP non-tolerant animals with reduced oxidative phosphorylation and increased uncoupled respiration. Complex I Vmax was reduced in septic animals; however, CLP animals sustained normal Vmax. Mitochondrial biogenesis was preserved in CLP-tolerant animals compared to the CLP-nontolerant group, likely due to increased TFAM expression. LPS tolerance protected septic animals from mitochondrial dysfunction, favoring mitochondrial biogenesis and preserving mitochondrial respiration and respiratory complex I activity.
PMID:38888558 | DOI:10.1097/SHK.0000000000002399
18 Jun 14:40
by Joshua Grabeck, Jacob Mayer, Axel Miltz, Michele Casoria, Michael Quagliata, Denise Meinberger, Andreas R. Klatt, Isabelle Wielert, Berenike Maier, Anna Maria Papini, and Ines Neundorf

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.4c00078